Assets
(4 total)
4Total Assets
0Approved
1Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Mutant IDH1Small molecule | Acute Myeloid Leukemia | |
| Phase 1/2 | KCNT1 mRNARNA / oligonucleotide | Epilepsy | |
| Phase 1/2 | RAFSmall molecule | Non-Small Cell Lung CancerAcute Myeloid Leukemia | |
| Phase 1/2 | Menin-KMT2A protein-protein interaction | Acute Myeloid Leukemia |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.